Clinical Trial Update: Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B [Phase 3]

View source ↗

Summary

Phase 3 trial status update for Fitusiran prophylaxis in male pediatric patients aged 1 to less than 12 years with Hemophilia A or B; the study is currently ACT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Fitusiran (fitusiran)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Hemophilia | Phase 3 | Status: ACTIVE_NOT_RECRUITING